
La Jolla Pharmaceutical Company LJPC
Quarterly report 2022-Q2
added 08-15-2022
La Jolla Pharmaceutical Company Operating Expenses 2011-2026 | LJPC
Annual Operating Expenses La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 61.4 M | 130 M | 202 M | 115 M | 79 M | 43 M | 21.3 M | 17.9 M | 10.7 M | 2.27 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 202 M | 2.27 M | 68.4 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.85 | 3.22 % | $ 9.26 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 327.0 | -1.92 % | $ 42.8 B | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 4.71 | -0.42 % | $ 766 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Cabaletta Bio
CABA
|
172 M | $ 3.52 | 3.38 % | $ 354 M | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.24 | 11.12 % | $ 81.5 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.94 | 1.2 % | $ 1.03 B | ||
|
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 100.85 | 1.39 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.13 | -3.52 % | $ 5.15 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | ||
|
Galectin Therapeutics
GALT
|
20.1 M | $ 2.34 | -8.79 % | $ 150 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
173 M | $ 1.4 | -10.0 % | $ 360 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.2 | -1.55 % | $ 3.08 B | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.59 | -1.1 % | $ 6.83 B | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.53 | 2.68 % | $ 407 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.66 | -0.62 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M |